Reversible coma caused by risperidone-ritonavir interaction

Clinical Neuropharmacology

Volumn 25, Issue 5, 2002, Pages 251-253

  Jover, Francisco ^a   Cuadrado, José María ^a   Andreu, Lucio ^a   Merino, Jaime ^a  

^a NONE   (Spain)

Author keywords

Cytochrome P 450; Drug interaction; Protease inhibitors; Risperidone; Ritonavir

Indexed keywords

CYTOCHROME P450; INDINAVIR; PROTEINASE INHIBITOR; RISPERIDONE; RITONAVIR;

ADULT; ARTICLE; CASE REPORT; COMA; COMPETITIVE INHIBITION; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; ENZYME INHIBITION; ENZYME SUBSTRATE; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; PROTEIN FAMILY; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; COMA; DRUG INTERACTIONS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; RISPERIDONE; RITONAVIR;

EID: 0036708871     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200209000-00004     Document Type: Article

References (16)

1. Rosholm JU, Hallas J and Gram LF. Concurrent use of more than one major psychotropic drug (polypsychopharmacy) in outpatients. A prescription database study. Br J Clin Pharmacol 1994;37:533-538.
2. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001;344:984-996.
3. Michalets EM. Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998;18:84-112.
4. Desta Z, Kerbusch T and Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizer of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther 1999;65:10-20.
5. Shin GK, Soukhova N, Flockhart DA. Effect of antypsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: Preferential inhibition of CYP2D6. Drug Metabolism and Disposition 1999;27:1078-84.
6. Ayuso JL. Use of psychotropic drugs in patients with HIV infection. Drugs 1994;47(4):599-610.
7. Cohen, LJ. Risperidone. Pharmacotherapy 1994;14:253.
8. Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 1999;359:147-51.
9. Belzie LR. Risperidone for AIDS-associated dementia: A case series. AIDS Patient Care STDS 1996;10:246-9.
10. Singh AN, Golledge H, Catalan J. Treatment of HIV-related psychotic disorders with risperidone: A series of 21 cases. J Psychosom Res 1997;42:489-93.
11. Singh AN, Catalan J. Risperidone in HIV-related manic psychosis. Lancet 1994;344:554-5.
12. Scordo MG, Spina E, Facciola G, et al. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl) 1999 Dec;147:300-5.
13. Bork JA, Rogers T, Wedlund PJ, et al. A pilot study on risperidone metabolism: The role of cytochromes P4502D6 and 3A. J Clin Psychiatry 1999 Jul;60:469-76.
14. Product information. Ritonavir (Norvir®). Abbott Labs. February 1996.
15. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other antiHIV agents. Clin Pharmacokinet 1998;35:275-91.
16. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimated the likehood of metabolic pharmacokinetic interaction. Clin Pharmacokinet 1997;32:210-258.